louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01804894: Do Common Physical Tests Predict Injury or Performance
Official title: Field Tests and Their Correlation With Injury and Performance
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Lower Extremity Musculoskeletal Injury
Lead sponsor: High Point University
Sponsor class: OTHER
First posted: 2013-03-05
Enrollment: 359
Sex: ALL
Minimum age (years): 18
Maximum age (years): 23
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: college age, varsity, division 1 athletes

Brief summary: Field tests are convenient, simple tests that serve as estimates of components of athletic performance like power speed, and agility. It is thought clinically, that those who do best at these tests will perform the best in their sport and/or be the least likely to get injured. The converse is also thought to be true. The objective of this study is to administer field tests to athletes at the beginning of each season and then follow athletes over several years, tracking their injuries and their performance statistics. In this way, the investigators can determine if the clinical supposition is true and that the results of field tests are associated with injury or performance

Detailed description: 11 physical performance tests were examined to determine their ability to predict injury

Eligibility criteria: Inclusion Criteria:

* age18-23
* member of the university's varsity teams

Exclusion Criteria:

* injured or recently injured prior to testing
* diagnosed current neurological issue
* recent (within 6 weeks) surgery where strenuous physical testing would be contraindicated

Primary outcomes:
measure: injury
timeFrame: 1 year
Secondary outcomes:
measure: performance
timeFrame: 1 season
Other outcomes:
measure: overuse injury by area of the body
timeFrame: 1 year
Locations:
city: High Point
country: United States
facility: High Point University
state: North Carolina
Study officials:
References:
citation: Dallinga JM, Benjaminse A, Lemmink KA. Which screening tools can predict injury to the lower extremities in team sports?: a systematic review. Sports Med. 2012 Sep 1;42(9):791-815. doi: 10.1007/BF03262295.
citation: Hegedus EJ, McDonough S, Bleakley C, Baxter GD, DePew JT, Bradbury I, Cook C. Physical performance tests predict injury in National Collegiate Athletic Association athletes: a three-season prospective cohort study. Br J Sports Med. 2016 Nov;50(21):1333-1337. doi: 10.1136/bjsports-2015-094885. Epub 2016 Jan 8.
Clinical trial NCT06769594: Next Generation CT System
Official title: Clinical Feasibility and Evaluation of Silicon Photon Counting CT
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Computed Tomography
Lead sponsor: GE Healthcare
Sponsor class: INDUSTRY
Collaborators: name: University of Wisconsin, Madison
First posted: 2025-01-10
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The subject population will consist of adults that are 18-years of age or older, and who have undergone a prior clinically indicated imaging exam of at least one of the following anatomical areas: head, neck, heart, chest, abdomen, pelvis, and/or extremities.

Brief summary: The purpose of the study is to collect data to evaluate utility of a next generation CT system in a clinical setting.

Detailed description: Data collected in this study includes an assessment of image quality parameters including spatial resolution, image contrast, and noise to evaluate the product. This data and analysis will help support regulatory submission.

Eligibility criteria: Inclusion Criteria:

Subjects may be included in this study if they meet the following criteria:

1. Who are 18 year of age or older;
2. Able to sign and date the informed consent form; AND
3. Who have in the past 120 days or will in the future 30 days from the day of consent undergo a clinically indicated imaging exam (MRI, CT, radiograph, nuclear medicine, ultrasound, bone material density, interventional radiology procedure) of the head, neck, heart, chest, abdomen, pelvis, or extremities where images are available for this prior exam.

Exclusion Criteria:

Subjects may be excluded from participating in study if they meet any of the following criteria:

1. Who are pregnant or lactating;
2. Who were previously enrolled in this study;
3. For contrast-enhanced CT exams, anyone with known or suspected allergy to iodinated contrast agents;
4. For contrast-enhanced CT exams, anyone with known or suspected renal insufficiency as determined by site medical personnel;
5. Who are in need of urgent or emergent care;
6. Who have any conditions that, in the opinion of the PI or designee, would interfere with the evaluation of the results or constitute a health hazard for the subject; and,
7. Who are unwilling to have GEHC personnel present for the CT exam.

Primary outcomes:
measure: Data Collection
timeFrame: 12 months
Secondary outcomes:
measure: Safety Information
timeFrame: 12 months
measure: Assessment of Image Quality
timeFrame: 12 months
Other outcomes:
Locations:
city: Madison
country: United States
facility: University of Wisconsin, Madison
state: Wisconsin
Study officials:
affiliation: GE Healthcare
name: MICT Global Research Manager
role: STUDY_DIRECTOR
References:
Clinical trial NCT04264494: Evaluating the Role of Intra-articular Injections of Platelet Rich Plasma (PRP) in Patients With Rheumatoid Arthritis.
Official title: Evaluating the Role of Intra-articular Injections of Platelet-rich Plasma (PRP) in Patients With Rheumatoid Arthritis and Its Impact on Disease Activity and Quality of Life.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: RA - Rheumatoid Arthritis
Lead sponsor: Menoufia University
Sponsor class: OTHER
First posted: 2020-02-11
Enrollment: 100
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To evaluate the therapeutic effect of 3 local doses of PRP intra-articular injection in patients with RA regarding the improvement of disease activity and quality of life versus placebo.

Detailed description: 100 patients with RA fulfilling the 2010 ACR-EULAR classification criteria for RA were recruited from the outpatient clinic of the Rheumatology and Rehabilitation department. All patients were subjected to clinical and laboratory assessment, visual analog score (VAS) scale and Health Assessment Questionnaire (HAQ). Fifty patients were injected intra-articularly with 3 doses of PRP and 50 patients who serve as a control injected with 3 doses of placebo at 4 weeks intervals for the tender joints and revaluated at 1, 3 months post the last injection regarding the same evaluating tools.

Eligibility criteria: Inclusion Criteria:

* patients diagnosed as RA regarding 2010 new criteria of RA, both sex,aged20-60 years old.

Exclusion Criteria:

* Patients with Local abscess,
* systemic illness as (diabetes mellitus, malignancy),
* patients on opioids analgesics.
* pregnancy, blood disorders(coagulopathy, thrombocytopenia),

Primary outcomes:
measure: visual analogue scale (VAS).
timeFrame: Change from baseline to 6 months post injection.
measure: Inflammatory mediators.
timeFrame: Change from baseline to 6 months post injection.
measure: Health assessment questionnaire disability index. (HAQ-DI)
timeFrame: Change from baseline to 6 months post injection.
Secondary outcomes:
measure: Disease Activity Score 28(DAS28)
timeFrame: At baseline,3 and 6 months post injection.
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Dalia Saif
Study officials:
References:
Clinical trial NCT02814994: Respiratory System Compliance Guided VT in Moderate to Severe ARDS Patients
Official title: Respiratory System Compliance Guided Tidal Volume in Moderate to Severe ARDS Patients: A Multicenter Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Respiratory Failure
Acute Respiratory Distress Syndrome
Keywords: Mechanical Ventilation
ARDS
Ventilator Strategy
Outcome
Lead sponsor: Southeast University, China
Sponsor class: OTHER
First posted: 2016-06-28
Enrollment: 242
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The Acute Respiratory Distress Syndrome (ARDS) is one of common clinical critically diseases. In the United States, the incidence of ARDS reaches 31%, which is one of the main causes of death in patients. There is no unified treatment process for ARDS currently and the treatment measures are not yet standardized, so the standardization of ARDS treatment processes is needed to reduce mortality in patients. Following the evidence-based medicine principles and six-step treatment standards of ARDS, this study uses the method of multi-center randomized controlled clinical trials to evaluate the standardized treatment process of ARDS, which provides the basis for the standardized treatment of ARDS.

Detailed description: From September 1st 2012 to September 30th 2014, all ARDS patients admitted to the ICUs will be enrolled. The demographic characteristics, diagnosis, formerly medical history, Ventilator indications, Ventilator data, other respiratory treatments, weaning outcome and 28 day mortality will be recorded.

Eligibility criteria: Inclusion Criteria:

1. aged ≥ 18 years
2. admitted to the ICU
3. according to the diagnostic criteria of ARDS Berlin definition，admit patients with severe ARDS

Exclusion Criteria:

1. age \<18 years old
2. be expected to die within 24 hours
3. end-stage malignancies
4. be participating in other studies, which may affect the results of this study
5. DNI (do not intubation) and DNR (do not recovery) patients
6. family members do not agree to sign an informed consent

Primary outcomes:
measure: the effects of tidal volume guided by respiratory system compliance on mortality in patients suffering from ARDS
timeFrame: 28-days
Secondary outcomes:
Other outcomes:
Locations:
city: Nanjing
country: China
facility: Zhongda Hospital
state: Jiangsu
Study officials:
affiliation: southeast university
name: Haibo Qiu, Prof.
role: STUDY_DIRECTOR
References:
Clinical trial NCT00746694: A Study to Determine the Management of Palmar-plantar Erythrodysesthesia (PPE) in Patients With Metastatic Ovarian or Breast Cancer Treated With Caelyx (Study P05020)
Official title: Epidemiological Study to Assess the Management of Palmar-plantar Erythrodysesthesia (PPE) in Patients With Metastatic Ovarian or Breast Cancer Treated With Pegylated Liposomal Doxorubicin
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Ovarian Neoplasms
Breast Neoplasms
Paresthesia
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2008-09-04
Enrollment: 154
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Participants with metastatic ovarian or breast cancer, to be recruited from the Oncology Departments of 16 centers for a period of 12 months.

Brief summary: The objective of this trial is to study the management of PPE in participants with metastatic ovarian or breast cancer treated with Caelyx, and determine the frequency of use of pharmacological treatment (preventive or therapeutic) for PPE and compliance of educational recommendations for PPE.


Eligibility criteria: Inclusion Criteria:

* Women 18 years of age or older.
* Participants with metastatic breast or ovarian cancer who are receiving treatment with pegylated liposomal doxorubicin.
* Participants who have given their written consent.

Exclusion Criteria:

* Participants who are currently participating in a clinical trial.

Primary outcomes:
measure: Number of Participants Who Received Concomitant Treatment Strategies to Manage Palmar-Plantar Erythrodysesthesia (PPE)
timeFrame: Participants will do a single visit, but cases will be collected during a period of 12 months.
measure: Number of Participants That Received Curative Treatment and/or Prophylaxis Treatment for PPE
timeFrame: Participants will do a single visit, but cases will be collected during a period of 12 months.
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00190294: Expectant Versus Immediate Medical Management for the Evacuation of the no Evolutionary Pregnancies Before 13 GW
Official title: Comparison Expectant With Immediate Medical Management for the Evacuation of the no Evolutionary Pregnancies Before 13 GW
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Pregnancy Complications
Keywords: Pregnancy Complications
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
First posted: 2005-09-19
Enrollment: 200
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 48
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Compared the interest of one week expectancy vs immediate medical treatment in the taking care of the evacuation of the no evolutionary pregnancies before 13 GW.

Detailed description: Randomized control trial comparing one week expectancy vs immediate medical treatment (mifepristone 200mg and misoprostol 400ug) in the taking care of the evacuation of the no evolutionary pregnancies before 13 GW.

Eligibility criteria: Inclusion Criteria:

* Agreed women aged over 18 yrs old

Non evolutive pregnancy before 13GW :

* Non evolutive pregnancy with no fetal cardiac activity
* Non evolutive pregnancy with embryonic structures
* Trophoblastic material in uterine cavity P bhCG \< 10UI/L

Exclusion criteria:

* Age \< 18 years
* pregnancy evolutionary
* not evolutionary pregnancy after 13 weeks of amenorrhoea characterized by the presence of an scan image intra-uterine ANECHOGENE furthermore of 50mm of diameter
* amenorrhoea of more than 13 weeks
* pregnancy twin
* pregnancy molar
* pregnancy extra-uterine
* Extra-uterine pregnancy
* one or many contraindications in the mifepristone:
* Allergy known about the MIFEPRISTONE
* Incapacity suprarenal
* corticosteroid therapy in the long price
* confusions of the haemostasis (thrombopenia \< in 100000 / mm3)
* anaemia (rate Hg \< in 9 g / dl)
* contraindication in the misoprostol
* allergy known about PROSTAGLANDINES
* BEANCE cervical

Primary outcomes:
measure: Number of surgical evacuation in each group
timeFrame: during de study
Secondary outcomes:
Other outcomes:
Locations:
city: Poissy
country: France
facility: Poissy Hospital
Study officials:
affiliation: Poissy Hospital
name: Patrick Rosenberg
role: STUDY_CHAIR
References:
citation: Ghosh J, Papadopoulou A, Devall AJ, Jeffery HC, Beeson LE, Do V, Price MJ, Tobias A, Tuncalp O, Lavelanet A, Gulmezoglu AM, Coomarasamy A, Gallos ID. Methods for managing miscarriage: a network meta-analysis. Cochrane Database Syst Rev. 2021 Jun 1;6(6):CD012602. doi: 10.1002/14651858.CD012602.pub2.
citation: Torre A, Huchon C, Bussieres L, Machevin E, Camus E, Fauconnier A. Immediate versus delayed medical treatment for first-trimester miscarriage: a randomized trial. Am J Obstet Gynecol. 2012 Mar;206(3):215.e1-6. doi: 10.1016/j.ajog.2011.12.009. Epub 2011 Dec 16.
Clinical trial NCT00058994: An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD
Official title: An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal Choroidal Neovascularization Due to Exudative Age-related Macular Degeneration
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Macular Degeneration
Maculopathy, Age-Related
Keywords: AMD
anecortave acetate
wet AMD
age-related macular degeneration
Macular Degeneration
Maculopathy, Age-Related
Age-Related Maculopathies
Age-Related Maculopathy
Maculopathies, Age-Related
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
First posted: 2003-04-16
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to demonstrate that anecortave acetate is superior to placebo in maintenance of visual acuity at the 12- and 24-month visits.


Eligibility criteria: Patients at least 50 years of age, of any race, and either sex with a clinical diagnosis of exudative AMD and a primary or recurrent subfoveal CNV lesion in the study eye.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Fort Worth
country: United States
facility: South America
state: Texas
Study officials:
affiliation: Alcon Research
name: Alcon Investigators
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06574594: Effect of MTX Discontinuation on Shingrix Response in RA
Official title: Effect of Methotrexate Discontinuation on Immunogenicity of Shingrix in Patients With Rheumatoid Arthritis
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Rheumatoid Arthritis
Keywords: herpes zoster
Shingrix
methotrexate
Lead sponsor: Konkuk University Medical Center
Sponsor class: OTHER
First posted: 2024-08-28
Enrollment: 110
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The goal of this clinical trial is to learn if methotrexate discontinuation affect on immunogeneity of shingrix in RA patients. The main questions it aims to answer are:

Discontinuation of methotrexate after shingrix immunization increase efficacy of the vaccine in patients with RA ?

Researchers will compare humoral and cell-mediated immunity against herpes zoster in RA patients who are vaccinated by shingrix, and compare these immunity between RA patients with MTX discontinuation and MTX continuation groups.

Participants will:

Vaccinated with shingrix twice. MTX continuation group will keep taking MTX after shingrix vaccination, whereas MTX discontinuation group will stop MTX for 2 weeks after shingrix vaccination.

Visit the clinic at baseline (first shingrix vaccination), 2 months later for 2nd shingrix vaccination, then 3 \& 6 months later from baseline to achieve blood sample.


Eligibility criteria: Inclusion Criteria:

* fulfill 2010 ACR/EULAR classification criteria for rheumatoid arthritis
* age over 19 years
* methotrexate user
* agree for vaccination with shingrix

Exclusion Criteria:

* have other form of inflammatory arthritis or autoimmune-mediated disease
* malignancy, current infection, pregnancy

Primary outcomes:
measure: Cell-mediated immunity (CD4+ and CD8+ T cell against herpes zoster)
timeFrame: baseline (before 1st vaccination), 1 months later from 2nd vaccination, 3 months later from 2nd vaccination
Secondary outcomes:
measure: , Humoral immunity (anti-VZV antibody, anti-gE antibody)
timeFrame: baseline (before 1st vaccination), 1 months later from 2nd vaccination, 3 months later from 2nd vaccination
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Konkuk University Medical Center
Study officials:
affiliation: Konkuk University Medical Center
name: Hong Ki Min, MD, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT06982794: A Patient-Directed Mobile Tool to Streamline the QoL Assessment and Monitoring in Urothelial Carcinoma
Official title: 'UROLIFE': a Patient-Directed Mobile Tool to Streamline the QoL Assessment and Monitoring in Urothelial Carcinoma
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Urothelial Carcinoma (UC)
Keywords: Quality of life
Self-education
Educational
Urothelial carcinoma
Web-app
Mobile tool
Design-thinking
Lead sponsor: IRCCS San Raffaele
Sponsor class: OTHER
First posted: 2025-05-21
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with a diagnosis of urothelial carcinoma and candidate to receive systemic treatments at the Ospedale San Raffaele Department of Medical Oncology, Milan (Italy).

Brief summary: The goal of this observational study is to select contents and tools for the future development of a web app aiming to support patients' navigation for empowering decision-making through a higher awareness of urothelial carcinoma and its treatments, improving also educational aspects.

The main question it aims to answer is:

What are the contents that patients diagnosed with urothelial carcinoma find useful to include in a web app to streamline their quality of life assessment and monitoring?

Participants candidate for systemic treatments, or already under treatment, will answer questionnaires about the tools to include in a web app designed for urothelial carcinoma.


Eligibility criteria: Inclusion Criteria:

* histological diagnosis of urothelial carcinoma;
* ≥ 18 years old,
* candidate for systemic treatment with chemotherapy, immune-checkpoint inhibitors, antibody-drug conjugates, or target therapy (patients can be enrolled also if the treatment has started),
* possession of a mobile device (e.g., smartphone or personal computer) with the physical and psychological ability to use mobile devices,
* understanding and speaking the Italian language,
* ability to sign an informed consent.

Exclusion Criteria:

* not possession of a mobile device,
* unwillingness to give informed consent.

Primary outcomes:
measure: Evaluation score for the Web App contents
timeFrame: 3 months
Secondary outcomes:
measure: eHealth Literacy Scale Score
timeFrame: 3 months
Other outcomes:
Locations:
city: Milan
country: Italy
facility: IRCCS San Raffaele
Study officials:
References: